{"id":"NCT03277196","sponsor":"Vertex Pharmaceuticals Incorporated","briefTitle":"A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Participants With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation","officialTitle":"A Phase 3, 2-Arm, Open-label Study to Evaluate the Safety and Pharmacodynamics of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-08-16","primaryCompletion":"2023-10-02","completion":"2023-10-02","firstPosted":"2017-09-08","resultsPosted":"2024-10-23","lastUpdate":"2024-10-23"},"enrollment":86,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis"],"interventions":[{"type":"DRUG","name":"IVA","otherNames":["VX-770","ivacaftor"]}],"arms":[{"label":"Ivacaftor Arm","type":"EXPERIMENTAL"},{"label":"Observational Arm","type":"NO_INTERVENTION"}],"summary":"This is a Phase 3, 2-arm, multicenter study with an open-label ivacaftor arm and an observational arm to evaluate the safety and efficacy of long-term ivacaftor treatment in participants with cystic fibrosis (CF) who are \\<24 months of age at treatment initiation and have an approved Ivacaftor-Responsive mutation.","primaryOutcome":{"measure":"Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs","timeFrame":"Day 1 up to Week 120","effectByArm":[{"arm":"Ivacaftor Treatment","deltaMin":85,"sd":null}],"pValues":[]},"eligibility":{"minAge":"0 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":9},"locations":{"siteCount":29,"countries":["United States","Australia","Canada","Germany","Ireland","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":86},"commonTop":["Cough","Pyrexia","Rhinorrhoea","Upper respiratory tract infection","Vomiting"]}}